Effect of Whole-Brain Radiotherapy Dose on the Occurrence of Otitis Media and Mastoiditis in Patients With Lung Cancer With Brain Metastasis

IF 3.1 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Cts-Clinical and Translational Science Pub Date : 2025-06-20 DOI:10.1111/cts.70269

Xudong Zhang, Ying Huang, Hongfei Li, Yuntong Pei, Fanyang Kong, Qian Zhang, Yadong Song, Yunji Wang, Guowen Li

{"title":"Effect of Whole-Brain Radiotherapy Dose on the Occurrence of Otitis Media and Mastoiditis in Patients With Lung Cancer With Brain Metastasis","authors":"Xudong Zhang, Ying Huang, Hongfei Li, Yuntong Pei, Fanyang Kong, Qian Zhang, Yadong Song, Yunji Wang, Guowen Li","doi":"10.1111/cts.70269","DOIUrl":null,"url":null,"abstract":"This study aims to investigate the incidence of acute mastoiditis in patients with brain metastases undergoing whole-brain radiotherapy (WBRT). A retrospective analysis was conducted on patients with brain metastases who received different doses of WBRT. The incidence of acute mastoiditis within 6 months post-radiotherapy was observed. Patients were divided into four groups based on the radiation dose: 25, 30, 36 and 40 Gy. The incidence of mastoiditis in each group was statistically analyzed. A total of 209 patients were followed up, with no cases lost to follow-up, and the follow-up time was 6 months. The results showed that the number of patients with middle ear mastoiditis was 6 (24%) in group A, 101 (67%) in group B, 12 (80%) in group C and 15 (83%) in group D, and there was a statistically significant difference between the four groups (χ2 = 22.525, p < 0.001). The incidence of acute mastoiditis in patients with brain metastases post-WBRT is positively correlated with the radiation dose. Higher doses not only increase the risk of mastoiditis but also potentially lead to more severe damage to the middle ear and mastoid regions. Therefore, careful dose management and preventive measures are recommended in WBRT planning to reduce the risk of such complications.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 6","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70269","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cts-Clinical and Translational Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cts.70269","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

This study aims to investigate the incidence of acute mastoiditis in patients with brain metastases undergoing whole-brain radiotherapy (WBRT). A retrospective analysis was conducted on patients with brain metastases who received different doses of WBRT. The incidence of acute mastoiditis within 6 months post-radiotherapy was observed. Patients were divided into four groups based on the radiation dose: 25, 30, 36 and 40 Gy. The incidence of mastoiditis in each group was statistically analyzed. A total of 209 patients were followed up, with no cases lost to follow-up, and the follow-up time was 6 months. The results showed that the number of patients with middle ear mastoiditis was 6 (24%) in group A, 101 (67%) in group B, 12 (80%) in group C and 15 (83%) in group D, and there was a statistically significant difference between the four groups (χ² = 22.525, p < 0.001). The incidence of acute mastoiditis in patients with brain metastases post-WBRT is positively correlated with the radiation dose. Higher doses not only increase the risk of mastoiditis but also potentially lead to more severe damage to the middle ear and mastoid regions. Therefore, careful dose management and preventive measures are recommended in WBRT planning to reduce the risk of such complications.

Abstract Image

查看原文本刊更多论文

全脑放疗剂量对肺癌脑转移患者中耳炎、乳突炎发生的影响

本研究旨在探讨全脑放疗（WBRT）脑转移患者急性乳突炎的发生率。对接受不同剂量WBRT治疗的脑转移患者进行回顾性分析。观察放疗后6个月内急性乳突炎的发生率。根据放疗剂量将患者分为25、30、36、40 Gy四组。统计分析各组乳突炎的发生率。共随访209例，无失访病例，随访时间6个月。结果显示，A组中耳乳突炎患者6例（24%），B组101例（67%），C组12例（80%），D组15例（83%），4组比较差异有统计学意义（χ2 = 22.525, p < 0.001）。脑转移术后急性乳突炎的发生率与放疗剂量呈正相关。较高的剂量不仅会增加患乳突炎的风险，而且可能会对中耳和乳突区域造成更严重的损害。因此，建议在WBRT计划中进行谨慎的剂量管理和预防措施，以减少此类并发症的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cts-Clinical and Translational Science 医学-医学：研究与实验

CiteScore

6.70

自引率

2.60%

发文量

234

审稿时长

6-12 weeks

期刊介绍： Clinical and Translational Science (CTS), an official journal of the American Society for Clinical Pharmacology and Therapeutics, highlights original translational medicine research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. Translational medicine is a multi-faceted discipline with a focus on translational therapeutics. In a broad sense, translational medicine bridges across the discovery, development, regulation, and utilization spectrum. Research may appear as Full Articles, Brief Reports, Commentaries, Phase Forwards (clinical trials), Reviews, or Tutorials. CTS also includes invited didactic content that covers the connections between clinical pharmacology and translational medicine. Best-in-class methodologies and best practices are also welcomed as Tutorials. These additional features provide context for research articles and facilitate understanding for a wide array of individuals interested in clinical and translational science. CTS welcomes high quality, scientifically sound, original manuscripts focused on clinical pharmacology and translational science, including animal, in vitro, in silico, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of both traditional drugs and innovative modalities.